untitled h1
12 references

1. Sugarbaker DJ, Garcia JP, Richards WG, Harpole DH, Jr., Healy-Baldini E, DeCamp MM, Jr., Mentzer SJ, Liptay MJ, Strauss GM, Swanson SJ. Extrapleural pneumonectomy in the multimodality therapy of malignant pleural mesothelioma. Results in 120 consecutive patients.  
Annals of surgery. 1996;224(3):288-94; discussion 94-6. PubMed PMID: 8813257; PMCID: 1235368. 2. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2003;21(14):2636-44. doi: 10.1200/JCO.2003.11.136. PubMed PMID: 12860938. 3. Moolgavkar SH, Meza R, Turim J. Pleural and peritoneal mesotheliomas in SEER: age effects and temporal trends, 1973-2005. Cancer causes & control : CCC. 2009;20(6):935-44. doi: 10.1007/s10552-009-9328-9. PubMed PMID: 19294523. 4. Yan TD, Deraco M, Baratti D, Kusamura S, Elias D, Glehen O, Gilly FN, Levine EA, Shen P, Mohamed F, Moran BJ, Morris DL, Chua TC, Piso P, Sugarbaker PH. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multiinstitutional experience. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009;27(36):6237-42. doi: 10.1200/JCO.2009.23.9640. PubMed PMID: 19917862. 5. Park BJ, Alexander HR, Libutti SK, Wu P, Royalty D, Kranda KC, Bartlett DL. Treatment of primary peritoneal mesothelioma by continuous hyperthermic peritoneal perfusion (CHPP). Annals of surgical oncology. 1999;6(6):582-90. PubMed PMID: 10493628. 6. Feldman AL, Libutti SK, Pingpank JF, Bartlett DL, Beresnev TH, Mavroukakis SM, Steinberg SM, Liewehr DJ, Kleiner DE, Alexander HR. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2003;21(24):4560-7. doi: 10.1200/JCO.2003.04.150. PubMed PMID: 14673042. 7. Loggie BW, Fleming RA, McQuellon RP, Russell GB, Geisinger KR, Levine EA. Prospective trial for the treatment of malignant peritoneal mesothelioma. The American surgeon. 2001;67(10):999-1003. PubMed PMID: 11603562. 8. Ordonez NG. Application of mesothelin immunostaining in tumor diagnosis. The American journal of surgical pathology. 2003;27(11):1418-28. PubMed PMID: 14576474. 9. Kelly RJ, Sharon E, Pastan I, Hassan R. Mesothelin-targeted agents in clinical trials and in preclinical development. Molecular cancer therapeutics. 2012;11(3):517-25. doi: 10.1158/15357163.MCT-11-0454. PubMed PMID: 22351743; PMCID: 3297681. 10. Pastan I, Hassan R. Discovery of mesothelin and exploiting it as a target for immunotherapy. Cancer research. 2014;74(11):2907-12. doi: 10.1158/0008-5472.CAN-14-0337. PubMed PMID: 24824231; PMCID: 4062095. 11. Weldon JE, Pastan I. A guide to taming a toxin--recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer. The FEBS journal. 2011;278(23):4683700. Epub 2011/05/19. doi: 10.1111/j.1742-4658.2011.08182.x. PubMed PMID: 21585657; PMCID: 3179548. 12. Hassan R, Bullock S, Premkumar A, Kreitman RJ, Kindler H, Willingham MC, Pastan I. Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007;13(17):5144-9. doi: 10.1158/1078-0432.CCR-07-0869. PubMed PMID: 17785569.  
13. Kreitman RJ, Hassan R, Fitzgerald DJ, Pastan I. Phase I trial of continuous infusion antimesothelin recombinant immunotoxin SS1P. Clinical cancer research : an official journal of the American Association for Cancer Research. 2009;15(16):5274-9. doi: 10.1158/1078-0432.CCR09-0062. PubMed PMID: 19671873; PMCID: 2754261.  
14. Hassan R, Bullock S, Premkumar A, Kreitman RJ, Kindler H, Willingham MC, Pastan I. Phase I study of SS1P a recombinant anti-mesothelin immunotoxin given as a bolus IV infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clinical Cancer Research. 2007;13(17):5144-9. doi: 10.1158/1078-0432.CCR-07-0869. PubMed PMID: WOS:000249287700029. 15. Oratz R, Speyer JL, Wernz JC, Hochster H, Meyers M, Mischak R, Spitler LE. Antimelanoma Monoclonal-Antibody Ricin-a Chain Immunoconjugate (Xmmme-001-Rta) Plus Cyclophosphamide in the Treatment of Metastatic Malignant-Melanoma - Results of a Phase-Ii Trial. J Biol Resp Modif. 1990;9(4):345-54. PubMed PMID: WOS:A1990DT07400001. 16. Selvaggi K, Saria EA, Schwartz R, Vlock DR, Ackerman S, Wedel N, Kirkwood JM, Jones H, Ernstoff MS. Phase I/Ii Study of Murine Monoclonal Antibody-Ricin-a Chain (XomazymeMel) Immunoconjugate Plus Cyclosporine-a in Patients with Metastatic Melanoma. J Immunother.  
1993;13(3):201-7. doi: Doi 10.1097/00002371-199304000-00007. PubMed PMID: WOS:A1993KU06500007. 17. Hassan R, Williams-Gould J, Watson T, Pai-Scherf L, Pastan I. Pretreatment with rituximab does not inhibit the human immune response against the immunogenic protein LMB-1. Clinical cancer research : an official journal of the American Association for Cancer Research. 2004;10(1 Pt 1):16-8. PubMed PMID: 14734446. 18. Mossoba ME, Onda M, Taylor J, Massey PR, Treadwell S, Sharon E, Hassan R, Pastan I, Fowler DH. Pentostatin plus cyclophosphamide safely and effectively prevents immunotoxin immunogenicity in murine hosts. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011;17(11):3697-705. doi: 10.1158/1078-0432.CCR-11-0493. PubMed PMID: 21521777; PMCID: 3107891. 19. Hassan R, Miller AC, Sharon E, Thomas A, Reynolds JC, Ling A, Kreitman RJ, Miettinen MM, Steinberg SM, Fowler DH, Pastan I. Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression. Science translational medicine. 2013;5(208):208ra147. doi: 10.1126/scitranslmed.3006941. PubMed PMID: 24154601. 20. Mazor R, Vassall AN, Eberle JA, Beers R, Weldon JE, Venzon DJ, Tsang KY, Benhar I, Pastan I. Identification and elimination of an immunodominant T-cell epitope in recombinant immunotoxins based on Pseudomonas exotoxin A. Proceedings of the National Academy of Sciences of the United States of America. 2012;109(51):E3597-603. doi: 10.1073/pnas.1218138109. PubMed PMID: 23213206; PMCID: 3529021. 21. Weldon JE, Xiang L, Zhang J, Beers R, Walker DA, Onda M, Hassan R, Pastan I. A recombinant immunotoxin against the tumor-associated antigen mesothelin reengineered for high activity, low off-target toxicity, and reduced antigenicity. Molecular cancer therapeutics. 2013;12(1):48-57. doi: 10.1158/1535-7163.MCT-12-0336. PubMed PMID: 23136186; PMCID: 3546136. 22. Liu W, Onda M, Lee B, Kreitman RJ, Hassan R, Xiang L, Pastan I. Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes. Proceedings of the National Academy of Sciences of the United States of America. 2012;109(29):11782-7. Epub 2012/07/04. doi: 10.1073/pnas.1209292109. PubMed PMID: 22753489; PMCID: 3406843. 23. Hollevoet K, Mason-Osann E, Liu XF, Imhof-Jung S, Niederfellner G, Pastan I. In vitro and in vivo activity of the low-immunogenic antimesothelin immunotoxin RG7787 in pancreatic cancer. Molecular cancer therapeutics. 2014;13(8):2040-9. doi: 10.1158/1535-7163.MCT-140089-T. PubMed PMID: 24928849; PMCID: 4142475. 24. Alewine C, Xiang L, Yamori T, Niederfellner G, Bosslet K, Pastan I. Efficacy of RG7787, a next-generation mesothelin-targeted immunotoxin, against triple-negative breast and gastric cancers. Molecular cancer therapeutics. 2014;13(11):2653-61. doi: 10.1158/1535-7163.MCT-140132. PubMed PMID: 25239937; PMCID: 4221527. 25. Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu Rev Immunol. 2003;21:685-711. doi: 10.1146/annurev.immunol.21.120601.141040. PubMed PMID: 12615891. 26. Maldonado RA, von Andrian UH. How tolerogenic dendritic cells induce regulatory T cells. Adv Immunol. 2010;108:111-65. doi: 10.1016/B978-0-12-380995-7.00004-5. PubMed PMID: 21056730; PMCID: PMC3050492. 27. Manicassamy S, Pulendran B. Dendritic cell control of tolerogenic responses. Immunol Rev. 2011;241(1):206-27. doi: 10.1111/j.1600-065X.2011.01015.x. PubMed PMID: 21488899; PMCID: PMC3094730. 28. Thomson AW, Turnquist HR, Raimondi G. Immunoregulatory functions of mTOR inhibition. Nat Rev Immunol. 2009;9(5):324-37. doi: 10.1038/nri2546. PubMed PMID: 19390566; PMCID: PMC2847476. 29. Taner T, Hackstein H, Wang Z, Morelli AE, Thomson AW. Rapamycin-treated, alloantigen-pulsed host dendritic cells induce ag-specific T cell regulation and prolong graft survival. Am J Transplant. 2005;5(2):228-36. doi: 10.1046/j.1600-6143.2004.00673.x. PubMed PMID: 15643982. 30. Kishimoto TK, Ferrari JD, LaMothe RA, Kolte PN, Griset AP, O'Neil C, Chan V, Browning E, Chalishazar A, Kuhlman W, Fu FN, Viseux N, Altreuter DH, Johnston L, Maldonado RA. Improving the efficacy and safety of biologic drugs with tolerogenic nanoparticles. Nat Nanotechnol. 2016;11(10):890-9. doi: 10.1038/nnano.2016.135. PubMed PMID: 27479756. 31. Ghisdal L, Van Laecke S, Abramowicz MJ, Vanholder R, Abramowicz D. New-onset diabetes after renal transplantation: risk assessment and management. Diabetes Care. 2012;35(1):181-8. doi: 10.2337/dc11-1230. PubMed PMID: 22187441; PMCID: PMC3241330. 32. Johnston O, Rose CL, Webster AC, Gill JS. Sirolimus is associated with new-onset diabetes in kidney transplant recipients. J Am Soc Nephrol. 2008;19(7):1411-8. doi: 10.1681/ASN.2007111202. PubMed PMID: 18385422; PMCID: PMC2440303. 33. Shivaswamy V. Immunosupppression and Endocrine Dysfunction. Journal of Transplantation Technologies & Research. 2013;01(S2). doi: 10.4172/2161-0991.s2-006. 34. Hakeam HA, Al-Jedai AH, Raza SM, Hamawi K. Sirolimus induced dyslipidemia in tacrolimus based vs. tacrolimus free immunosuppressive regimens in renal transplant recipients. Ann Transplant. 2008;13(2):46-53. PubMed PMID: 18566560. 35. Barlow AD, Nicholson ML, Herbert TP. Evidence for rapamycin toxicity in pancreatic beta-cells and a review of the underlying molecular mechanisms. Diabetes. 2013;62(8):2674-82. doi: 10.2337/db13-0106. PubMed PMID: 23881200; PMCID: PMC3717855. 36. Pereira MJ, Palming J, Rizell M, Aureliano M, Carvalho E, Svensson MK, Eriksson JW. mTOR inhibition with rapamycin causes impaired insulin signalling and glucose uptake in human subcutaneous and omental adipocytes. Mol Cell Endocrinol. 2012;355(1):96-105. doi: 10.1016/j.mce.2012.01.024. PubMed PMID: 22333157. 37. Soefje SA, Karnad A, Brenner AJ. Common toxicities of mammalian target of rapamycin inhibitors. Target Oncol. 2011;6(2):125-9. doi: 10.1007/s11523-011-0174-9. PubMed PMID: 21499766. 38. Siegall CB, Liggitt D, Chace D, Mixan B, Sugai J, Davidson T, Steinitz M. Characterization of vascular leak syndrome induced by the toxin component of Pseudomonas exotoxin-based immunotoxins and its potential inhibition with nonsteroidal anti-inflammatory drugs. Clinical cancer research : an official journal of the American Association for Cancer Research. 1997;3(3):339-45. Epub 1997/03/01. PubMed PMID: 9815690. 39. Kuan CT, Pai LH, Pastan I. Immunotoxins containing Pseudomonas exotoxin that target LeY damage human endothelial cells in an antibody-specific mode: relevance to vascular leak syndrome. Clinical cancer research : an official journal of the American Association for Cancer Research. 1995;1(12):1589-94. Epub 1995/12/01. PubMed PMID: 9815960. 40. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). European journal of cancer. 2009;45(2):228-47. doi: 10.1016/j.ejca.2008.10.026. PubMed PMID: 19097774. 41. Byrne MJ, Nowak AK. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2004;15(2):257-60. PubMed PMID: 14760119. 42. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A, Hussain M, Prostate Cancer Clinical Trials Working G. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008;26(7):1148-59. doi: 10.1200/JCO.2007.12.4487. PubMed PMID: 18309951; PMCID: PMC4010133. 43. Rustin GJ, Quinn M, Thigpen T, du Bois A, Pujade-Lauraine E, Jakobsen A, Eisenhauer E, Sagae S, Greven K, Vergote I, Cervantes A, Vermorken J. Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). Journal of the National Cancer Institute. 2004;96(6):487-8. PubMed PMID: 15026475. 44. Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, Figg WD, Freidlin B, Halabi S, Hudes G, Hussain M, Kaplan R, Myers C, Oh W, Petrylak DP, Reed E, Roth B, Sartor O, Scher H, Simons J, Sinibaldi V, Small EJ, Smith MR, Trump DL, Wilding G, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1999;17(11):3461-7. doi: 10.1200/JCO.1999.17.11.3461. PubMed PMID: 10550143. 45. Vergote I, Rustin GJ, Eisenhauer EA, Kristensen GB, Pujade-Lauraine E, Parmar MK, Friedlander M, Jakobsen A, Vermorken JB. Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup. Journal of the National Cancer Institute. 2000;92(18):1534-5. PubMed PMID: 10995813.  
46. Roa J, Garcia-Galiano D, Varela L, Sanchez-Garrido MA, Pineda R, Castellano JM, RuizPino F, Romero M, Aguilar E, Lopez M, Gaytan F, Dieguez C, Pinilla L, Tena-Sempere M. The mammalian target of rapamycin as novel central regulator of puberty onset via modulation of hypothalamic Kiss1 system. Endocrinology. 2009;150(11):5016-26. doi: 10.1210/en.2009-0096. PubMed PMID: 19734277.
untitled h1
13 appendices

| 13.1                                                                                                                                                            | APPENDIX A-PERFORMANCE STATUS CRITERIA                                  |                                                                    |                 |           |             |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------|--------------------------------------------------------------------|-----------------|-----------|-------------|
| ECOG Performance Status Scale                                                                                                                                   | Karnofsky Performance Scale                                             |                                                                    |                 |           |             |
| Grade                                                                                                                                                           | Descriptions                                                            | Percent                                                            | Description     |           |             |
| 100                                                                                                                                                             | Normal,                                                                 | no                                                                 | complaints,     | no        |             |
| evidence of disease.                                                                                                                                            |                                                                         |                                                                    |                 |           |             |
| Normal activity. Fully active, able                                                                                                                             |                                                                         |                                                                    |                 |           |             |
| 0                                                                                                                                                               | to                                                                      | carry                                                              | on              | all       | pre-disease |
| performance without restriction.                                                                                                                                | Able to carry on normal activity;                                       |                                                                    |                 |           |             |
| 90                                                                                                                                                              | minor                                                                   | signs                                                              | or              | symptoms  | of          |
| disease.                                                                                                                                                        |                                                                         |                                                                    |                 |           |             |
| Symptoms,                                                                                                                                                       | but                                                                     | ambulatory.                                                        |                 |           |             |
| Restricted in physically strenuous  activity, but ambulatory and able  to carry out work of a light or  sedentary nature (e.g., light  housework, office work). | 80                                                                      | Normal activity with effort; some  signs or symptoms of disease.   |                 |           |             |
| 1                                                                                                                                                               | Cares for self, unable to carry on                                      |                                                                    |                 |           |             |
| 70                                                                                                                                                              | normal activity or to do active  work.  Requires occasional assistance, |                                                                    |                 |           |             |
| 60                                                                                                                                                              | but is able to care for most of  his/her needs.                         |                                                                    |                 |           |             |
| In                                                                                                                                                              | bed                                                                     | <50%                                                               | of              | the       | time.       |
| Ambulatory and capable of all  self-care, but unable to carry out  any work activities. Up and about  more than 50% of waking hours.                            |                                                                         |                                                                    |                 |           |             |
| 2                                                                                                                                                               | 50                                                                      | Requires considerable assistance  and frequent medical care.       |                 |           |             |
| 40                                                                                                                                                              | Disabled, requires special care  and assistance.                        |                                                                    |                 |           |             |
| In bed >50% of the time. Capable  of only limited self-care, confined  to bed or chair more than 50% of  waking hours.                                          |                                                                         |                                                                    |                 |           |             |
| 3                                                                                                                                                               | 30                                                                      | Severely disabled, hospitalization  indicated. Death not imminent. |                 |           |             |
| 20                                                                                                                                                              | Very                                                                    | sick,                                                              | hospitalization |           |             |
| indicated. Death not imminent.                                                                                                                                  |                                                                         |                                                                    |                 |           |             |
| 100%                                                                                                                                                            | bedridden.                                                              | Completely                                                         |                 |           |             |
| disabled.                                                                                                                                                       | Cannot carry on any                                                     |                                                                    |                 |           |             |
| self-care. Totally confined to bed  or chair.                                                                                                                   |                                                                         |                                                                    |                 |           |             |
| 4                                                                                                                                                               | 10                                                                      | Moribund,                                                          | fatal           | processes |             |
| progressing rapidly.                                                                                                                                            |                                                                         |                                                                    |                 |           |             |
| 5                                                                                                                                                               | Dead.                                                                   | 0                                                                  | Dead.           |           |             |  
13.2 APPENDIX B - **COCKROFT-GAULT FORMULA**  
| Creatine Clearance =   | (140 - age) x weight in kg (x 0.85 for females)  (serum creatinine x 72)   |
|------------------------|----------------------------------------------------------------------------|